A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

Pfizer1,100 enrolled

Overview

To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,100

Conditions

Diabetes Mellitus

Interventions

Inhaled InsulinDRUG

Eligibility

Sex: ALLMin age: 35 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes mellitus Type 2 * Failing two or more oral anti-diabetic agents Exclusion Criteria: * Asthma, COPD * Smoking

Locations (121)

Outcomes

Primary Outcomes

Glycosylated hemoglobin

Secondary Outcomes

Percent of patients achieving good control of fasting glucose and lipids

Rate of hypoglycemia

Changes in body weight

Patient satisfaction

Safety based on adverse events reported and laboratory tests

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Pfizer Investigational Site

La Jolla, California, United States

Pfizer Investigational Site

San Diego, California, United States

Pfizer Investigational Site

Washington D.C., District of Columbia, United States

Pfizer Investigational Site

Jacksonville, Florida, United States

Pfizer Investigational Site

Jacksonville, Florida, United States

Pfizer Investigational Site

Miami, Florida, United States

Pfizer Investigational Site

Columbus, Georgia, United States

Pfizer Investigational Site

Overland Park, Kansas, United States

Pfizer Investigational Site

New Orleans, Louisiana, United States

Pfizer Investigational Site

Baltimore, Maryland, United States

...and 111 more locations